Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Cardiol Therapeutics Inc.
  6. News
  7. Summary
    CRDL   CA14161Y2006

CARDIOL THERAPEUTICS INC.

(CRDL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Original-Research : Cardiol Therapeutics (von GBC AG): BUY

06/23/2021 | 09:04am EDT

Original-Research: Cardiol Therapeutics - von GBC AG

Einstufung von GBC AG zu Cardiol Therapeutics

Unternehmen: Cardiol Therapeutics ISIN: CA14161Y2006

Anlass der Studie: Initial Coverage Report Empfehlung: BUY seit: 23.06.2021 Kursziel: 15,77 CAD Kursziel auf Sicht von: 31.12.2021 Letzte Ratingänderung: - Analyst: Julien Desrosiers; Felix Haugg

One Product in two formulations, heart disease treatments in the making

Cardiol Therapeutics provides leadership in therapeutic trials using Cannabidiol to take advantage of major opportunities in inflammatory heart disease.

The company has an exclusive manufacturing agreement for a Cannabidiol pharmaceutical formulation which is highly concentrated and THC free (<10 ppm).

There is a considerable quantity of scientific evidence showing that using Cannabidiol can be beneficial as an anti-inflammatory agent.

The management has a proven track record of strong leadership coupled with substantial industry knowledge and competence in commercializing proprietary medications.

The team enrolled their first patients in LANCER, a Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19 in April 2021.

The phase I Single and Multiple Ascending Dose Clinical Trial showed successful Topline results for CardiolRx(TM) in April 2021.

The company applied for uplisting on the NASDAQ in March 2021.

Cardiol Therapeutics has one product on the market in Canada, Cortalex(TM) CBD, exclusively available online at Medical Cannabis by Shoppers Inc.

The company raised over 50M CAD during the past 12 months, with just over 53M total shares outstanding allowing for maximum future value creation for shareholders.

Our estimates project considerable cumulative earnings of 2.982M CAD for the next 10 years with an 85% average margin.

They have a unique opportunity to leverage the well documented and discussed benefits of Cannabidiol for three different cardiovascular disease markets, each in dire need of effective treatment.

We believe the company to be an early takeover target in case of positive results of their COVID-19 Phase II/III trials.

Price target: 15,77 CAD, Rating: BUY

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/22609.pdf

Kontakt für Rückfragen GBC AG Halderstraße 27 86150 Augsburg 0821 / 241133 0 research@gbc-ag.de +++++++++++++++ Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,5b,6a,6b,7,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter: http://www.gbc-ag.de/de/Offenlegung +++++++++++++++ Date (time) of completion of English version: 23/06/2021 (01:30 pm) Date (time) of first distribution of English version: 23/06/2021 (03:00 pm)

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

(END) Dow Jones Newswires

June 23, 2021 09:03 ET (13:03 GMT)

All news about CARDIOL THERAPEUTICS INC.
09/16CARDIOL THERAPEUTICS : to Participate in the 2021 CantorVirtual Global Healthcare Conferen..
PU
09/16CARDIOL THERAPEUTICS : to Participate in the 2021 Cantor Virtual Global Healthcare Confere..
PU
09/13CARDIOL THERAPEUTICS INC. (VON GBC A : Kaufen
DJ
09/10CARDIOL THERAPEUTICS : Announces Acceleration ofExpiry Date of Warrants issued on June 4, ..
PU
09/10CARDIOL THERAPEUTICS : Announces Acceleration of Expiry Date of Warrants issued on June 4,..
PU
09/09CARDIOL THERAPEUTICS (VON GBC AG) : Buy
DJ
09/07CARDIOL THERAPEUTICS : Appoints Michael J. Willner to its Board of Directors (Form 6-K)
PU
09/07Cardiol Therapeutics Inc. Announces Board Changes
CI
09/07CARDIOL THERAPEUTICS : Appoints Michael J. Willner to its Board of Directors
PU
09/02CARDIOL THERAPEUTICS : MATERIAL CHANGE REPORT (Form 6-K)
PU
More news
Analyst Recommendations on CARDIOL THERAPEUTICS INC.
More recommendations
Financials
Sales 2021 0,87 M 0,69 M 0,69 M
Net income 2021 -18,4 M -14,5 M -14,5 M
Net Debt 2021 - - -
P/E ratio 2021 -9,87x
Yield 2021 -
Capitalization 229 M 180 M 180 M
Capi. / Sales 2021 262x
Capi. / Sales 2022 15,5x
Nbr of Employees -
Free-Float 89,7%
Chart CARDIOL THERAPEUTICS INC.
Duration : Period :
Cardiol Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARDIOL THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 5,33 CAD
Average target price 11,66 CAD
Spread / Average Target 119%
EPS Revisions
Managers and Directors
David G. Elsley President, Chief Executive Officer & Director
Christopher J. Waddick Chief Financial Officer & Secretary
Daniel Crandall Finance Director
Guillermo Torre-Amione Chairman
Anthony E. Bolton Director of Research
Sector and Competitors
1st jan.Capi. (M$)
CARDIOL THERAPEUTICS INC.91.73%181
JOHNSON & JOHNSON4.75%433 991
ROCHE HOLDING AG10.87%324 441
PFIZER, INC.19.40%247 760
NOVO NORDISK A/S51.58%233 750
ELI LILLY AND COMPANY37.51%210 490